Galectin Therapeutics (GALT) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $3.71, +1.92% vs the prior close of $3.64.
- Volume 119.20K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GALT rises 1.9% to $3.71. Closed at $3.71, +1.92% vs the prior close of $3.64. Day range $3.66–$3.84, opened at $3.68.
GALT daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — GALT rises 1.9% to $3.71
- Closed at $3.71, +1.92% vs the prior close of $3.64. Day range $3.66–$3.84, opened at $3.68.
- Volume was 119.20K shares, 0.4x its 50-day average of 304.67K — lighter than usual.
- Price is -2.7% vs its 50-day average ($3.81) and +15.4% vs its 200-day average ($3.22).
- 52-week range $2.03–$7.13; today's close sits at 33% of that range, 48.0% below the 52-week high.
Oct 14, 2026 — GALT dips 1.4% to $3.64, 3 down days in a row
- Closed at $3.64, -1.36% vs the prior close of $3.69. Day range $3.61–$3.86, opened at $3.66.
- Volume was 409.00K shares, 1.3x its 50-day average of 313.37K.
- Price is -4.2% vs its 50-day average ($3.80) and +13.2% vs its 200-day average ($3.22).
- 52-week range $2.03–$7.13; today's close sits at 32% of that range, 48.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — GALT slides 4.7% to $3.69
- Closed at $3.69, -4.65% vs the prior close of $3.87. Day range $3.67–$3.86, opened at $3.84.
- Volume was 184.40K shares, 0.6x its 50-day average of 315.62K — lighter than usual.
- Price is -2.5% vs its 50-day average ($3.79) and +14.6% vs its 200-day average ($3.22).
- 52-week range $2.03–$7.13; today's close sits at 33% of that range, 48.2% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 12, 2026 — GALT dips 1.8% to $3.87
- Closed at $3.87, -1.78% vs the prior close of $3.94. Day range $3.84–$4.01, opened at $3.92.
- Volume was 99.70K shares, 0.3x its 50-day average of 321.38K — lighter than usual.
- Price is +2.6% vs its 50-day average ($3.77) and +20.2% vs its 200-day average ($3.22).
- 52-week range $2.03–$7.13; today's close sits at 36% of that range, 45.7% below the 52-week high.
Oct 9, 2026 — GALT jumps 8.2% to $3.94
- Closed at $3.94, +8.24% vs the prior close of $3.64. Day range $3.64–$3.97, opened at $3.64.
- Volume was 156.40K shares, 0.5x its 50-day average of 326.32K — lighter than usual.
- Price is +4.9% vs its 50-day average ($3.75) and +22.3% vs its 200-day average ($3.22).
- 52-week range $2.03–$7.13; today's close sits at 37% of that range, 44.7% below the 52-week high.
Oct 8, 2026 — GALT rises 0.6% to $3.64
- Closed at $3.64, +0.55% vs the prior close of $3.62. Day range $3.51–$3.69, opened at $3.62.
- Volume was 270.80K shares, 0.8x its 50-day average of 327.51K.
- Price is -2.7% vs its 50-day average ($3.74) and +13.0% vs its 200-day average ($3.22).
- 52-week range $2.03–$7.13; today's close sits at 32% of that range, 48.9% below the 52-week high.
Oct 7, 2026 — GALT slides 3.7% to $3.62, a 1-month low
- Closed at $3.62, -3.72% vs the prior close of $3.76. Day range $3.59–$3.86, opened at $3.74.
- Volume was 176.00K shares, 0.5x its 50-day average of 329.18K — lighter than usual.
- Price is -3.1% vs its 50-day average ($3.74) and +12.2% vs its 200-day average ($3.23).
- 52-week range $2.03–$7.13; today's close sits at 31% of that range, 49.2% below the 52-week high.
Oct 6, 2026 — GALT rises 0.8% to $3.76
- Closed at $3.76, +0.80% vs the prior close of $3.73. Day range $3.57–$3.79, opened at $3.75.
- Volume was 277.90K shares, 0.8x its 50-day average of 329.68K.
- Price is +0.7% vs its 50-day average ($3.73) and +16.1% vs its 200-day average ($3.24).
- 52-week range $2.03–$7.13; today's close sits at 34% of that range, 47.3% below the 52-week high.
Oct 5, 2026 — GALT slides 4.4% to $3.73
- Closed at $3.73, -4.36% vs the prior close of $3.90. Day range $3.64–$3.90, opened at $3.84.
- Volume was 280.70K shares, 0.8x its 50-day average of 330.33K.
- Price is +0.1% vs its 50-day average ($3.73) and +14.7% vs its 200-day average ($3.25).
- 52-week range $2.03–$7.13; today's close sits at 33% of that range, 47.7% below the 52-week high.
Oct 2, 2026 — GALT jumps 3.7% to $3.90
- Closed at $3.90, +3.72% vs the prior close of $3.76. Day range $3.75–$3.94, opened at $3.82.
- Volume was 220.10K shares, 0.7x its 50-day average of 332.65K.
- Price is +4.8% vs its 50-day average ($3.72) and +19.5% vs its 200-day average ($3.26).
- 52-week range $2.03–$7.13; today's close sits at 37% of that range, 45.3% below the 52-week high.
GALT latest news & SEC filings
Every SEC filing by or about GALT in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form ARS — Annual report to shareholders
Annual report to shareholders
Oct 13, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Oct 13, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 2, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$9.11M (prior year -$7.52M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$0.12) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.02 — Sold unregistered shares.
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jamil Khurram sold 16,250 shares at $5.13 (≈$83.36K) on Jul 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Shlevin Harold H. sold 22,268 shares at $5.04 (≈$112.23K) on Jun 29, 2026
- Shlevin Harold H. sold 7,732 shares at $5.00 (≈$38.66K) on Jun 26, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 30, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jamil Khurram sold 47,467 shares at $5.04 (≈$239.23K) on Jun 29, 2026
- Jamil Khurram sold 2,037 shares at $5.00 (≈$10.19K) on Jun 26, 2026
- Jamil Khurram sold 2,533 shares at $5.00 (≈$12.66K) on Jun 26, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 29, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 26, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade GALT
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 31, 2026, Nov 14, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.67% (largest 8.2%).
- Liquidity: about 254.84K shares (≈$945.46K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $3.71 vs a range of $2.03–$7.13 (33% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 6 open-market buys, 19 sales; latest: Khurram Jamil sold 16,250 shares on Jul 14, 2026.
- Latest filings: 8-K Aug 14, 2026; 10-Q Aug 14, 2026; 8-K Aug 4, 2026.
- Share count: 100.85M shares outstanding (Aug 6, 2026), +57.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
GALT market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 3.68 | 3.84 | 3.66 | 3.71 | 119.20K |
| Oct 14, 2026 | 3.66 | 3.86 | 3.61 | 3.64 | 409.00K |
| Oct 13, 2026 | 3.84 | 3.86 | 3.67 | 3.69 | 184.40K |
| Oct 12, 2026 | 3.92 | 4.01 | 3.84 | 3.87 | 99.70K |
| Oct 9, 2026 | 3.64 | 3.97 | 3.64 | 3.94 | 156.40K |
| Oct 8, 2026 | 3.62 | 3.69 | 3.51 | 3.64 | 270.80K |
| Oct 7, 2026 | 3.74 | 3.86 | 3.59 | 3.62 | 176.00K |
| Oct 6, 2026 | 3.75 | 3.79 | 3.57 | 3.76 | 277.90K |
| Oct 5, 2026 | 3.84 | 3.90 | 3.64 | 3.73 | 280.70K |
| Oct 2, 2026 | 3.82 | 3.94 | 3.75 | 3.90 | 220.10K |
| Oct 1, 2026 | 3.87 | 4.06 | 3.68 | 3.76 | 327.40K |
| Sep 30, 2026 | 3.90 | 4.05 | 3.82 | 3.88 | 198.10K |
| Sep 29, 2026 | 3.94 | 4.00 | 3.90 | 3.91 | 174.20K |
| Sep 28, 2026 | 3.86 | 3.99 | 3.80 | 3.93 | 168.80K |
| Sep 25, 2026 | 3.93 | 3.99 | 3.86 | 3.90 | 124.60K |
| Sep 24, 2026 | 4.00 | 4.04 | 3.78 | 3.96 | 153.30K |
| Sep 23, 2026 | 4.12 | 4.15 | 4.00 | 4.05 | 174.00K |
| Sep 22, 2026 | 4.05 | 4.24 | 4.05 | 4.14 | 258.00K |
| Sep 21, 2026 | 3.91 | 4.02 | 3.85 | 3.96 | 258.40K |
| Sep 18, 2026 | 3.71 | 3.92 | 3.68 | 3.89 | 1.07M |
About Galectin Therapeutics
Galectin Therapeutics (GALT) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NORCROSS, GA. State of incorporation: NV. Fiscal year ends December 31. SEC CIK 1133416.
GALT board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gilbert F Amelio | Director | Jan 21, 2026 |
| Henry Brem | Director | Mar 17, 2026 |
| Benjamin Sr Carson | Director | Jan 21, 2026 |
| Kary Eldred | Director | Feb 9, 2026 |
| Kevin D Freeman | Director | Jan 21, 2026 |
| Joel Lewis | President and CEO | Jan 22, 2026 |
| Gilbert S Omenn | Director | Jan 21, 2026 |
| Elissa J. Schwartz | Director | Jan 21, 2026 |
| Harold H. Shlevin | Director | Jun 30, 2026 |
| Richard E Uihlein | Director | Aug 4, 2026 |
| Richard A. Jr. Zordani | Director | Jan 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jack W Callicutt | Chief Financial Officer | Jan 21, 2026 |
| Khurram Jamil | Chief Medical Officer | Jul 16, 2026 |
| Joel Lewis | President and CEO | Jan 22, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 14, 2026 | Khurram Jamil | Sale | 16,250 | $5.13 |
| Jun 29, 2026 | Harold H. Shlevin | Sale | 22,268 | $5.04 |
| Jun 29, 2026 | Khurram Jamil | Sale | 47,467 | $5.04 |
| Jun 26, 2026 | Harold H. Shlevin | Sale | 7,732 | $5.00 |
| Jun 26, 2026 | Khurram Jamil | Sale | 2,037 | $5.00 |
| Jun 26, 2026 | Khurram Jamil | Sale | 2,533 | $5.00 |
| Jun 23, 2026 | Khurram Jamil | Sale | 7,557 | $3.14 |
| May 26, 2026 | Khurram Jamil | Sale | 568 | $3.10 |
| Feb 6, 2026 | Kary Eldred | Buy | 300 | $2.70 |
| Jan 6, 2026 | Khurram Jamil | Sale | 21,446 | $3.65 |
| Jan 6, 2026 | Joel Lewis | Sale | 37,698 | $3.58 |
| Jan 6, 2026 | Jack W Callicutt | Sale | 20,354 | $3.67 |
| Jan 5, 2026 | Khurram Jamil | Sale | 25,499 | $3.90 |
| Jan 5, 2026 | Joel Lewis | Sale | 27,731 | $3.91 |
| Jan 5, 2026 | Jack W Callicutt | Sale | 25,732 | $3.90 |
GALT financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-30.84M | -0.48 | $-23.88M |
| Dec 31, 2024 | — | $-47.05M | -0.76 | $-41.77M |
| Dec 31, 2023 | — | $-41.07M | -0.74 | $-32.97M |
| Dec 31, 2022 | — | $-38.78M | -0.65 | $-31.06M |
| Dec 31, 2021 | — | $-30.53M | -0.52 | $-24.31M |
Latest balance sheet: total assets $14.83M, total liabilities $151.68M, cash $13.27M (as of Jun 30, 2026).
GALT earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $3.44 |
| May 15, 2026 | 8-K Item 2.02 (results) | $2.17 |
| Mar 31, 2026 | 8-K Item 2.02 (results) | $2.79 |
| Nov 14, 2025 | 8-K Item 2.02 (results) | $5.51 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $3.76 |
| May 15, 2025 | 8-K Item 2.02 (results) | $1.32 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $1.22 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $2.75 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 13, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on GALT
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.